Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary T Ferguson

Showing results (91-100 of 103) with videos related to

Pageof 11
Sort By:
International Journal of Chronic Obstructive Pulmonary Disease|January 11, 2020
Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD: A Subgroup Analysis of the KRONOS StudyMasakazu Ichinose, Yasushi Fukushima, Yoshikazu Inoue, et al.
International Journal of Chronic Obstructive Pulmonary Disease|January 11, 2020
Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPDMasakazu Ichinose, Yasushi Fukushima, Yoshikazu Inoue, et al.
Respiratory Research|May 31, 2020
Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trialsGary T Ferguson, Nicola Brown, Chris Compton, et al.
Respiratory Research|September 3, 2016
Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPDLeonardo M Fabbri, Edward M Kerwin, Selwyn Spangenthal, et al.
American Journal of Respiratory and Critical Care Medicine|November 30, 2020
Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group StudyFernando J Martinez, Klaus F Rabe, Gary T Ferguson, et al.
The New England Journal of Medicine|June 25, 2020
Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPDKlaus F Rabe, Fernando J Martinez, Gary T Ferguson, et al.
Respiratory Research|January 8, 2017
A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary diseaseColin Reisner, Leonardo M Fabbri, Edward M Kerwin, et al.
Respiratory Research|August 23, 2017
Erratum to: A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary diseaseColin Reisner, Leonardo M Fabbri, Edward M Kerwin, et al.
International Journal of Chronic Obstructive Pulmonary Disease|January 13, 2022
Measuring Peak Inspiratory Flow in Patients with Chronic Obstructive Pulmonary DiseaseJill A Ohar, Gary T Ferguson, Donald A Mahler, et al.
Chest|December 6, 2016
Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPDFernando J Martinez, Klaus F Rabe, Gary T Ferguson, et al.
Pageof 11

Showing results (91-100 of 103) with videos related to

Sort By:
Pageof 11
International Journal of Chronic Obstructive Pulmonary Disease|January 11, 2020
Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD: A Subgroup Analysis of the KRONOS StudyMasakazu Ichinose, Yasushi Fukushima, Yoshikazu Inoue, et al.
International Journal of Chronic Obstructive Pulmonary Disease|January 11, 2020
Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPDMasakazu Ichinose, Yasushi Fukushima, Yoshikazu Inoue, et al.
Respiratory Research|May 31, 2020
Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trialsGary T Ferguson, Nicola Brown, Chris Compton, et al.
Respiratory Research|September 3, 2016
Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPDLeonardo M Fabbri, Edward M Kerwin, Selwyn Spangenthal, et al.
American Journal of Respiratory and Critical Care Medicine|November 30, 2020
Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group StudyFernando J Martinez, Klaus F Rabe, Gary T Ferguson, et al.
The New England Journal of Medicine|June 25, 2020
Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPDKlaus F Rabe, Fernando J Martinez, Gary T Ferguson, et al.
Respiratory Research|January 8, 2017
A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary diseaseColin Reisner, Leonardo M Fabbri, Edward M Kerwin, et al.
Respiratory Research|August 23, 2017
Erratum to: A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary diseaseColin Reisner, Leonardo M Fabbri, Edward M Kerwin, et al.
International Journal of Chronic Obstructive Pulmonary Disease|January 13, 2022
Measuring Peak Inspiratory Flow in Patients with Chronic Obstructive Pulmonary DiseaseJill A Ohar, Gary T Ferguson, Donald A Mahler, et al.
Chest|December 6, 2016
Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPDFernando J Martinez, Klaus F Rabe, Gary T Ferguson, et al.
Pageof 11